Tag: #PI3K/AKT

One-year of Herceptin preferable to two-year regimen

Survival in hormone receptor-positive, HER2-negative advanced breast cancer is improved with the addition of capivasertib to fulvestrant therapy

byKassandra McFarlaneand1 others

June 26, 2023

1 .Progression-free survival is improved in patients receiving fulvestrant-capivasertib therapy as compared to fulvestrant-placebo treatment. 2. Overall survival at 18 ...

#VisualAbstract: Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone

byMinjee Kim

July 28, 2021

1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: #PI3K/AKT

Survival in hormone receptor-positive, HER2-negative advanced breast cancer is improved with the addition of capivasertib to fulvestrant therapy

#VisualAbstract: Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports